ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.

MLA

Georgiou, Marina, et al. “ATR and CDK4/6 Inhibition Target the Growth of Methotrexate-Resistant Choriocarcinoma.” Oncogene, vol. 41, no. 18, Apr. 2022, pp. 2540–54. EBSCOhost, https://doi.org/10.1038/s41388-022-02251-8.

APA

Georgiou, M., Ntavelou, P., Stokes, W., Roy, R., Maher, G. J., Stoilova, T., Choo, J. A. M. Y., Rakhit, C. P., Martins, M., Ajuh, P., Horowitz, N., Berkowitz, R. S., Elias, K., Seckl, M. J., & Pardo, O. E. (2022). ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Oncogene, 41(18), 2540–2554. https://doi.org/10.1038/s41388-022-02251-8

Chicago

Georgiou, Marina, Panagiota Ntavelou, William Stokes, Rajat Roy, Geoffrey J Maher, Tsvetana Stoilova, Josephine A M Y Choo, et al. 2022. “ATR and CDK4/6 Inhibition Target the Growth of Methotrexate-Resistant Choriocarcinoma.” Oncogene 41 (18): 2540–54. doi:10.1038/s41388-022-02251-8.